EMA-raadpleging: ontwerp kwalificatieoordeel van klinisch interpreteerbare behandeleffect maatregelen
The European Medicines Agency has released for public consultation a draft qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses.
Comments should be provided using this template and sent to Qualification@ema.europa,eu by 9 October 2019.
Please note that EMA may collect and further process some personal data of stakeholders and interested parties who submit contributions to the consultations. For more information, see Specific privacy statement for public consultations.
For more information on the European regulatory system for medicines, please click here (brochure available in all languages).